Search
forLearn
1 / 1 resultsResearch
5 / 27 resultsresearch Objective Outcome Measures: Collecting Meaningful Data on Alopecia Areata
The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Biotechs Target Stagnant Baldness Market
New drug shows promise for better hair growth in baldness treatment.
research Physician and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries
Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.
research Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey
Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
Community Join
5 / 30 resultscommunity Winlevi coming out in 2019
The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.
community Disappointing news on Breezula/CB-03-01
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
community Anyone else crying themselves to sleep because of the pyrilutamide fail?
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.
community CB-03-01: I need help
The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.
community SHISEIDO is A Bust...
Shiseido's hair loss treatment reported only 5% regrowth, disappointing many. Users discussed other treatments like Minoxidil, finasteride, RU58841, and CB-03-01 as potential alternatives.